Pronitazene Stats & Data
CCCOc1ccc(cc1)Cc1nc2cc(ccc2n1CCN(CC)CC)N(=O)=OSJHUJFHOXYDSJY-UHFFFAOYSA-NEffect Profile
CuratedStrong euphoria with strong itching/nausea, mild sedation and pain relief
Tolerance & Pharmacokinetics
drugs.wikiNo tolerance chart. Our decay curves for opioids were estimates, and a curve can make tolerance look longer-lasting than it is, which is the dangerous direction.
Opioid tolerance drops fast when you stop, and even a few days off can be enough, so a dose that used to be normal can now stop your breathing. Overdose deaths rise sharply after prison, detox or leaving treatment, and tolerance also falls during a hospital stay. After any break, start with a much smaller amount, try a test dose first, don't use alone, and keep naloxone within reach. Alcohol, benzodiazepines, gabapentinoids and other sedatives make an opioid overdose much more likely.
Sources: FRANK: heroin · National Harm Reduction Coalition · WHO: opioid overdose · Merrall et al. 2010 · Binswanger et al. 2007 · Strang et al. 2003 · FDA 2019: gabapentinoids and breathing
Cross-Tolerances
Harm Reduction
drugs.wikiName harmonized to Protonitazene (Pronitazene is a common synonym/variant); authoritative databases list Protonitazene as the preferred name. Nitazenes (including protonitazene) are highly potent and have been increasingly detected in Europe and North America, often in counterfeit or mis-sold products (e.g., heroin lookalikes and fake oxycodone/benzodiazepine tablets). Fentanyl test strips do not detect nitazenes; do not rely on them to rule out nitazenes—use laboratory-grade drug checking where available. Due to potency, active at double-digit microgram doses with a steep dose–response; volumetric dosing and calibrated 0.1 mg (or better) scales are strongly advised. Overdose management: initial response is the same as for other opioids; multiple naloxone doses may be required for reversal with potent synthetic opioids; provide rescue breathing and seek emergency care. Nitazenes often co-occur with other CNS depressants (e.g., benzodiazepines, xylazine); such combinations substantially increase overdose risk. Multiple naloxone administrations may be needed and monitoring after reversal is important because naloxone’s duration is shorter than many opioids. Powder and tablets containing nitazenes have been confirmed by drug checking services in fake oxycodone and other pills; assume unknowns contain high-potency opioids unless proven otherwise. Human pharmacokinetics for protonitazene remain poorly characterized; avoid redosing to ‘chase’ effects. Powder appearance or color is not a reliable indicator of content; only lab testing can confirm identity.
References
Cited references
- PubChem – Protonitazene compound page
- EUDA/EMCDDA – European Drug Report 2025: key developments (naloxone guidance, nitazene notes)
- EUDA/EMCDDA – New psychoactive substances (nitazenes, fake medicines, 2024–2025)
- EUDA – Drug-induced deaths (Baltic nitazene impacts)
- EUDA – Letter to Lancet Public Health editors: nitazenes in Estonia/Latvia deaths
- Toronto Drug Checking – nitazenes in ‘not-expected’ opioid samples (incl. isotonitazene/protonitazene)
- Toronto Drug Checking – N-desethyl etonitazene & protonitazepyne notice (context on high-potency nitazenes)
- Hi-Ground nitazenes harm-reduction sheet (FTS do not detect nitazenes)
- TripSit – Opioids HR (general naloxone, depressant mixing cautions)
- Bluelight – Etonitazene analogues megathread (user reports on microgram activity; caution)